In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity
about
CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cellsImpaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Immunosuppressive strategies that are mediated by tumor cellsMyelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cellsImmunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axisMyeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma modelTLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivoHow Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4(+) T cell receptor repertoire clonalityThe tumor-draining lymph node as an immune-privileged site.Signaling defects in anti-tumor T cellsAttenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.The challenge of the microenvironment in B-cell lymphomas.Bead-selected antitumor genetic cell vaccines.Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model
P2860
Q24681974-17F7133A-C7F3-48EC-980E-000CAC3D5B95Q27003955-94E48916-DC61-4CE8-8BFA-880E1BC4F4FEQ29636247-B01E4D2C-4FE9-488F-8FE9-4E5EE4603E01Q33800466-4B4D9862-5AA6-4734-BFE4-50F36D0FBC6FQ33838944-CFD2728B-8BB7-448B-80FC-C188536E9ED8Q33919954-A53E28C9-8D1F-4D4F-BD35-C1A3A1358996Q34028436-CF313B60-DD21-4D63-97F2-F01602DD3CAAQ34320769-0F57E77C-CA25-49F9-AFC4-EC19D90CC614Q34418112-4C9B863E-8021-4916-AF51-9ADFD002EEC8Q35990678-53B7FB50-89AA-481B-B098-75A993D2516EQ36004284-C4B51385-CCB9-4651-A71F-4ACB206E9E7FQ36249440-C640F96C-964E-4A8C-A78D-BE7D789BCBE7Q36256308-BF0C0013-7C1E-45E2-A201-BDE1C32C0080Q36593753-B19E78C6-29DB-4ADA-997D-687810E9FCB5Q37063739-7097DC63-C79A-4893-ABE1-D41B9B648911Q37188161-BC384527-B4C9-462F-8EB6-4766DC26B77AQ37598949-8E7E7F37-1F8E-4D36-AFF2-5FC393D4707DQ37831956-CEFFF243-53DC-4FDC-9B79-61AF49E57D80Q38260681-3E451B0F-0A7E-4764-BA81-A0CF7D1F34DBQ38810148-836CA91B-BE15-4D1B-AF76-19DA9DAB7983Q39093893-70992876-F8FE-41FF-AC3C-B345595BB8BAQ39234383-804797CD-33AD-41EF-A247-09C17CD32973
P2860
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
In vivo disruption of toleroge ...... leading to antitumor immunity
@ast
In vivo disruption of toleroge ...... leading to antitumor immunity
@en
type
label
In vivo disruption of toleroge ...... leading to antitumor immunity
@ast
In vivo disruption of toleroge ...... leading to antitumor immunity
@en
prefLabel
In vivo disruption of toleroge ...... leading to antitumor immunity
@ast
In vivo disruption of toleroge ...... leading to antitumor immunity
@en
P2093
P2860
P1433
P1476
In vivo disruption of toleroge ...... leading to antitumor immunity
@en
P2093
Alex Cuenca
Eduardo M Sotomayor
Fengdong Cheng
Hong-Wei Wang
Hyam Levitsky
Ivan Borrello
Jason Brayer
Pedro Horna
P2860
P304
P356
10.1182/BLOOD-2005-07-3014
P407
P577
2005-12-08T00:00:00Z